Since antibodies have exquisite specificity of target recognition and, thus, generate highly selective outcomes following their systemic administration, our purpose was to develop a "universal" osteoclast-targeting platform as a drug-delivery strategy in order to deliver antiresorptive drugs using an anti-RANK mAb capable of localizing to the cells responsible for bone resorption. We have chosen salmon calcitonin as a model drug, as it acts on the calcitonin receptor also found on bone-resorbing osteoclasts.